Table 1.
Patient characteristics
| MOSAIC Trial Stage II CC patients (N = 899) | ||
|---|---|---|
| Age at inclusion, years | ≤ 70 | 798 (88.77%) |
| > 70 | 101 (11.23%) | |
| Gendera | Female | 407 (45.27%) |
| Male | 492 (54.73%) | |
| Body mass indexa | Underweight | 27 (3%) |
| Normal | 438 (48.72%) | |
| Overweight | 324 (36.04%) | |
| Obese | 110 (12.24%) | |
| Type of adjuvant chemotherapya | FOLFOX4 | 451 (50.17%) |
| LV5FU2 | 448 (49.83%) | |
| Tumour locationa | Left | 580 (64.52%) |
| Right | 319 (35.48%) | |
| Histoprognostic grade | G1/2 | 763 (89.55%) |
| G3/4 | 89 (10.45%) | |
| Missing | 47 | |
| Stage II risk group | Highb | 434 (48.65%) |
| (MOSAIC definition) | Lowc | 458 (51.35%) |
| Missing | 7 | |
| Stage II risk group | High | 520 (58.3%) |
| (modified MOSAIC definition) | Low | 372 (41.7%) |
| Missing | 7 | |
| T-stagea | T3 | 728 (80.98%) |
| T4 | 171 (19.02%) | |
| Number of nodes examineda | Median (IQR) | 12 (8–19) |
| Performance status* | 0–1 | 799 (88.9%) |
| ≥ 2 | 100 (11.1%) | |
| Bowel perforationa | 81 (9.01%) | |
| Bowel obstructiona | 158 (17.58%) | |
| Vascular invasion | Yes | 80 (16.29%) |
| Missing | 408 | |
| MMR status | dMMR | 48 (13.15%) |
| pMMR | 317 (86.85%) | |
| Missing | 534 | |
| CEA level, ng/mL | Median (IQR) | 1.4 (0.9–2.2) |
| standard CEA cut-off level, ng/mL | ≤ 5 | 834 (96.19%) |
| > 5 | 33 (3.81%) | |
| CEA cut-off level reported by Margalit et al., ng/mL |
≤ 2.35 > 2.35 |
664 (76.6%) 203 (23.4%) |
| CEA cut-off level according to Hothorn method, ng/mL |
≤ 2.77 > 2.77 Missing |
724 (83.51%) 143 (16.49%) 32 |
| Time between surgery and CEA measurement, weeks | Median (IQR) | 4.4 (3.3–5.4) |
| Follow-up, years Median | Median | 8.8 (7.9–9.5) |
CC colon cancer, MMR mismatch repair, CEA carcinoembryonic antigen, CI confidence interval, IQR interquartile range
ano missing data
bT4, tumour perforation, or fewer than 10 lymph nodes examined
cT1–3 and no tumour perforation and 10 or more lymph nodes examine